Oruka Therapeutics, Inc.

ORKA Healthcare Biotechnology

EPS
−19.6%
Free cash flow
−43.0%

Quarter to June 2026, against a year earlier

102.68 6.66 +6.94%
Market cap
$6.4B
P/E
0.0×
Fwd P/E
—
Dividend yield
0.00%
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Current Ratio
22.37 28.89 59.01 37.72 15.56 14.28 9.16 8.55 5.94 8.95
Net Debt/EBITDA
2.65 4.16 5.21 4.05 2.77 5.07 1.46 0.82 0.64 1.31
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE
(24.86%) (40.22%) (13.57%) (21.41%) (39.61%) (35.98%) (80.37%) (97.30%) (113.89%) (54.57%)
ROA
(23.84%) (38.59%) (13.19%) (20.26%) (36.68%) (33.03%) (71.38%) (82.68%) (99.96%) (51.23%)
ROIC
(56.55%) (837.93%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% (1,007.09%)
Return on Tangible Assets
(32.07%) (23.00%) (14.44%) (23.87%) (37.91%) (20.95%) (72.47%) (132.04%) (180.02%) (86.03%)
Free Cash Flow per Share
(1.94) (3.46) (4.18) (9.09) (16.24) (19.74) (43.68) (128.67) (361.80) (357.12)
Book value per Share
10.35 22.77 30.83 34.72 44.07 118.59 69.18 94.10 212.73 528.43
Free Cash Flow
(88.42) (58.03) (5.01) (10.91) (18.80) (7.74) (4.80) (8.25) (17.47) (15.00)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 26 Oct 2026